Cisplatin and Etoposide Chemotherapy Combined with Early Concurrent Twice-daily Thoracic Radiotherapy for Limited-disease Small Cell Lung Cancer in Elderly Patients
| Autor: | Yasumasa Nishimura, Isamu Okamoto, Ken Takezawa, Izumi Tachibana, Masahiro Fukuoka, Kazuhiko Nakagawa, Kunio Okamoto |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Male
Oncology Cancer Research medicine.medical_specialty Lung Neoplasms medicine.medical_treatment Antineoplastic Agents Neutropenia Internal medicine Antineoplastic Combined Chemotherapy Protocols Humans Medicine Radiology Nuclear Medicine and imaging Progression-free survival Prospective cohort study Etoposide Aged Neoplasm Staging Retrospective Studies Chemotherapy business.industry General Medicine medicine.disease Small Cell Lung Carcinoma Survival Analysis Chemotherapy regimen humanities Female Cisplatin business Chemoradiotherapy Febrile neutropenia medicine.drug |
| Zdroj: | Japanese Journal of Clinical Oncology. 40:54-59 |
| ISSN: | 1465-3621 0368-2811 |
| DOI: | 10.1093/jjco/hyp137 |
| Popis: | Objective: The optimal management of elderly patients with limited-disease small cell lung cancer (LD-SCLC) has not been established. Methods: The records of elderly (� 70 years of age) patients with LD-SCLC who had been treated with etoposide and cisplatin chemotherapy with early concurrent twice-daily thoracic radiotherapy (TRT) were reviewed retrospectively. Results: Of the 25 elderly patients with LD-SCLC identified, 12 (48%) individuals received etoposide‐cisplatin chemotherapy with early concurrent twice-daily TRT. The main toxicities of this treatment regimen were hematologic, with neutropenia of Grade 4 being observed in all patients and febrile neutropenia of Grade 3 in eight patients during the first cycle of chemoradiotherapy. The toxicity of TRT was acceptable, with all patients completing the planned radiotherapy within a median of 29 days (range, 19‐33). No treatment-related deaths were observed. The median progression-free survival and overall survival times were 14.2 months (95% confidence interval, 4.3‐18.2) and 24.1 months (95% confidence interval, 11.3‐27.2), respectively. Conclusions: Etoposide‐cisplatin chemotherapy with early concurrent twice-daily TRT was highly myelotoxic in elderly patients with LD-SCLC, although no treatment-related deaths were observed in our cohort. Prospective studies are required to establish the optimal schedule and dose of chemotherapy and TRT in such patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|